Targetsite Therapeutics Corporation

New Haven, CT

UEI
HUAKPCHL21Q6
CAGE
8G8U0
Primary NAICS
541714 Research and Development in Biotechnology (except Nanobiotechnology)
SAM.gov registration
Active through

Company facts

Self-certified in SAM.gov
  • For Profit Organization
Entity structure
Corporate Entity (Not Tax Exempt)
SAM.gov registration date
Physical address
300 George St, New Haven, CT 06511, USA

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Grant awards

Award Agency Obligated Awarded
IL-17A mrna-targeted oligonucleotide therapeutics in idiopathic pulmonary fibrosis (IPF) R43HL170910 National Heart Lung and Blood Institute (NIH) $490,000
IL-23 and IL-17A mrna-targeted oligonucleotide therapeutics in autoimmune uveitis - the pro-inflammatory cytokines… R43EY032840 National Eye Institute (NIH) $959,382

SBA capabilities narrative

From the vendor's SBA profile

Corporation is a biotech company developing novel therapeutics. It is an RNA focused immunology platform with application across a number of indications.

Quick answers

Is Targetsite Therapeutics Corporation registered in SAM.gov?

Yes. Targetsite Therapeutics Corporation's SAM.gov registration is active through September 9, 2027.

What is Targetsite Therapeutics Corporation's most recent federal award?

Targetsite Therapeutics Corporation's most recent federal grant award is IL-17A mrna-targeted oligonucleotide therapeutics in idiopathic pulmonary fibrosis (IPF) (R43HL170910), from National Heart Lung and Blood Institute (NIH), on August 18, 2023.

On GovTribe

See Targetsite Therapeutics Corporation's full federal record

  • Federal grant awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors
Try for free Login